Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study.
Benthe H KönigHelen R GosseltJette A van LintLeanne J KosseBartholomeus J F van den BemtPeter M Ten KloosterHarald E VonkemanNaomi T JessurunPublished in: Expert opinion on drug safety (2024)
Patient-reported burden of ADRs attributed to the use of a TNF-α inhibitor in patients with IRDs decreased significantly over time, especially for infections and infestations.